These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 30985223)

  • 1. Effectiveness of etanercept biosimilar SB4 in maintaining low disease activity in patients with psoriatic arthritis switched from etanercept originator: an open-label one year study.
    Bonifati C; De Felice C; Lora V; Morrone A; Graceffa D
    J Dermatolog Treat; 2020 Nov; 31(7):687-691. PubMed ID: 30985223
    [No Abstract]   [Full Text] [Related]  

  • 2. Comparative Effectiveness and Persistence of SB4 and Reference Etanercept in Patients With Psoriatic Arthritis in Norway.
    Łosińska K; Pripp AH; Bakland G; Fevang BS; Brekke LK; Wierød A; Korkosz M; Haugeberg G
    Arthritis Care Res (Hoboken); 2024 Sep; 76(9):1303-1312. PubMed ID: 38600298
    [TBL] [Abstract][Full Text] [Related]  

  • 3. To switch or not to switch: results of a nationwide guideline of mandatory switching from originator to biosimilar etanercept. One-year treatment outcomes in 2061 patients with inflammatory arthritis from the DANBIO registry.
    Glintborg B; Loft AG; Omerovic E; Hendricks O; Linauskas A; Espesen J; Danebod K; Jensen DV; Nordin H; Dalgaard EB; Chrysidis S; Kristensen S; Raun JL; Lindegaard H; Manilo N; Jakobsen SH; Hansen IMJ; Dalsgaard Pedersen D; Sørensen IJ; Andersen LS; Grydehøj J; Mehnert F; Krogh NS; Hetland ML
    Ann Rheum Dis; 2019 Feb; 78(2):192-200. PubMed ID: 30396903
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical experience with the etanercept biosimilar SB4 in psoriatic patients.
    Pescitelli L; Lazzeri L; Di Cesare A; Tripo L; Ricceri F; Prignano F
    Int J Clin Pharm; 2019 Feb; 41(1):9-12. PubMed ID: 30610544
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Open-Label, Non-Mandatory Transitioning From Originator Etanercept to Biosimilar SB4: Six-Month Results From a Controlled Cohort Study.
    Tweehuysen L; Huiskes VJB; van den Bemt BJF; Vriezekolk JE; Teerenstra S; van den Hoogen FHJ; van den Ende CH; den Broeder AA
    Arthritis Rheumatol; 2018 Sep; 70(9):1408-1418. PubMed ID: 29609207
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Post-switch Effectiveness of Etanercept Biosimilar Versus Continued Etanercept in Rheumatoid Arthritis Patients with Stable Disease: A Prospective Multinational Observational Study.
    Pope J; Hall S; Bombardier C; Haraoui B; Jones G; Naik L; Etzel CJ; Ramey DR; Infante R; Miguelez M; Falcao S; Sahakian S; Wu D
    Adv Ther; 2022 Nov; 39(11):5259-5273. PubMed ID: 36136243
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of a single switch from etanercept originator to etanercept biosimilar in a cohort of inflammatory arthritis.
    Ditto MC; Parisi S; Priora M; Sanna S; Peroni CL; Laganà A; D'Avolio A; Fusaro E
    Sci Rep; 2020 Sep; 10(1):16178. PubMed ID: 32999362
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Costs associated with non-medical switching from originator to biosimilar etanercept in patients with rheumatoid arthritis in the UK.
    Tarallo M; Onishchenko K; Alexopoulos ST
    J Med Econ; 2019 Nov; 22(11):1162-1170. PubMed ID: 31373527
    [No Abstract]   [Full Text] [Related]  

  • 9. 52-week results of the phase 3 randomized study comparing SB4 with reference etanercept in patients with active rheumatoid arthritis.
    Emery P; Vencovský J; Sylwestrzak A; Leszczynski P; Porawska W; Baranauskaite A; Tseluyko V; Zhdan VM; Stasiuk B; Milasiene R; Barrera Rodriguez AA; Cheong SY; Ghil J
    Rheumatology (Oxford); 2017 Dec; 56(12):2093-2101. PubMed ID: 28968793
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Acceptance rate and sociological factors involved in the switch from originator to biosimilar etanercept (SB4).
    Scherlinger M; Langlois E; Germain V; Schaeverbeke T
    Semin Arthritis Rheum; 2019 Apr; 48(5):927-932. PubMed ID: 30093238
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biosimilar versus originator etanercept: a real-life clinical study.
    Giordano D; Capalbo A; Gagliostro N; Fedele G; Balampanos CG; Persechino F; Bushati V; Ulisse S; Persechino S; Pellacani G
    Ital J Dermatol Venerol; 2022 Aug; 157(4):318-324. PubMed ID: 35274881
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Outcomes following switching from etanercept originator to etanercept biosimilar in 1024 patients with RA: a matched-analysis of the BSRBR-RA.
    Kearsley-Fleet L; Rokad A; Tsoi MF; Zhao SS; Lunt M; Watson KD; ; Hyrich KL
    Rheumatology (Oxford); 2024 Aug; 63(8):2082-2092. PubMed ID: 37672014
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Does a mandatory non-medical switch from originator to biosimilar etanercept lead to increase in healthcare use and costs? A Danish register-based study of patients with inflammatory arthritis.
    Glintborg B; Ibsen R; Bilbo REQ; Lund Hetland M; Kjellberg J
    RMD Open; 2019; 5(2):e001016. PubMed ID: 31452931
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biosimilars for the treatment of psoriatic arthritis.
    Cantini F; Benucci M; Li Gobbi F; Franchi G; Niccoli L
    Expert Rev Clin Immunol; 2019 Nov; 15(11):1195-1203. PubMed ID: 31625769
    [No Abstract]   [Full Text] [Related]  

  • 15. Comparative effectiveness of etanercept originator and biosimilar for treating rheumatoid arthritis: implications for cost-savings.
    Deakin CT; Littlejohn GO; Griffiths H; Ciciriello S; O'Sullivan C; Smith T; Youssef P; Bird P;
    Intern Med J; 2024 May; 54(5):795-801. PubMed ID: 38009675
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mandatory, cost-driven switching from originator etanercept to its biosimilar SB4: possible fallout on non-medical switching.
    Cantini F; Benucci M
    Ann Rheum Dis; 2020 Feb; 79(2):e13. PubMed ID: 30487149
    [No Abstract]   [Full Text] [Related]  

  • 17. Etanercept (SB4): A Review in Autoimmune Inflammatory Diseases.
    Burness CB; Duggan ST
    BioDrugs; 2016 Aug; 30(4):371-8. PubMed ID: 27455991
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of switching from originator etanercept to biosimilar YLB113 in real-world patients with rheumatoid arthritis: A retrospective 12 months follow-up study.
    Sakane H; Yonemoto Y; Okamura K; Suto T; Inoue M; Mitomi H; Tsuchida K; Kaneko T; Tamura Y; Chikuda H
    J Orthop Surg (Hong Kong); 2024; 32(2):10225536241265818. PubMed ID: 38907590
    [No Abstract]   [Full Text] [Related]  

  • 19. Uptake and Spending on Biosimilar Infliximab and Etanercept After New Start and Switching Policies in Canada: An Interrupted Time Series Analysis.
    McClean AR; Cheng L; Bansback N; Clement F; Tadrous M; Harrison M; Law MR
    Arthritis Care Res (Hoboken); 2023 Sep; 75(9):2011-2021. PubMed ID: 36752358
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effectiveness and Persistence in SB4- and Reference Etanercept-Treated Rheumatoid Arthritis Patients in Ordinary Clinical Practice in Norway.
    Haugeberg G; Bakland G; Rødevand E; Hansen IJW; Diamantopoulos A; Pripp AH
    Arthritis Care Res (Hoboken); 2023 Sep; 75(9):1986-1995. PubMed ID: 36722450
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.